Open Access Open Access  Restricted Access Subscription or Fee Access

Recent Studies of Drugs in Asthma

K.P. Sathish, S. Kameshwaran, S.M. Shabariraj, A. Saranya, S. Shameem, K. Shanmugapriya


Asthma is a complex illness with a wide range of severity and symptoms. The most prevalent chronic illness impacting children is noncommunicable disease (NCD), which also affects adults. The tiny airways in the lungs become inflamed and constrict, triggering the asthma symptoms, such as coughing, wheezing, shortness of breath, and tightness in the chest. Bronchodilators cause the smooth muscles that surround the airway to relax. The airways enlarge and can now hold more air as a result. However, corticosteroids cannot stop an assault that has already started. These medications can be ingested, injected, or inhaled. Regular use of Cromolyn is also used to prevent asthma attacks, either by itself or in conjunction with other asthma medications.


Asthma, bronchodilators, corticosteroids, cromolyn, inflammation

Full Text:



Weinberger M, Hendeles L. Management of asthma. 2. Antiasthmatic drugs. Postgrad Med. 1977 May; 61(5): 95–100, 103. DOI: 10.1080/00325481.1977.11712185.

Encyclopedia of children’s health. Antiasthmatic Drugs. [Online]. http://www.healthofchildren. com/A/Antiasthmatic-Drugs.html. Retrieved on:19 Jun 2023.

Alicia Padilla Galo, Marina Labor, Angelica Tiotiu, Ilaria Baiardini, Nicola Scichilone, Fulvio Braido. Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives. Patient Relat Outcome Meas. 2018 Aug 17; 9: 267–273. Dove Medical Press. Doi: 10.2147/PROM.S146966.

Drug bank. Reslizumab. [Online]. Retrieved on: 25 Jun 2023. 5. Selina Hom, Michele Pisano. Reslizumab (Cinqair). PT. 2017 Sep; 42(9): 564–568. Retrieved on:25 Jun 2023.

Mayo clinic. Drugs supplements: Reslizumab: Intravenous route: side effects. [Online]. Retrieved on:26 Jun 2023.

RxWiki. Reslizumab. [Online]. Retrieved on:26 Jun 2023.

Pavord Ian D, Andrew Menzies-Gow, Roland Buhl, Pascal Chanez, Mark Dransfield, Njira Lugogo, Oliver N Keene, Bradford Eric S, Yancey Steve W. Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine. J Allergy Clin Immunol. 2021 Mar;

(3): 1121–1132.e7. DOI: 10.1016/j.jaip.2020.08.039. 9. Retrieved on: 26 Jun 2023. Mepolizumab (Monograph). [Online]. mepolizumab.html. Retrieved on:27 Jnn 2023.

Nucala. Severe Asthma: Risks and Side Effects. [Online]. Retrieved on:27 Jun 2023.

Mayo clinic. Drugs and Supplements: Mepolizumab Subcutaneous Route. [Online]. Retrieved on:27 Jun 2023.

Kavanagh Joanne E, Hearn Andrew P, Jaideep Dhariwal, Gráinne d'Ancona, Abdel Douiri, Cris Roxas, Mariana Fernandes, Linda Green, Louise Thomson, Nanzer Alexandra M, Kent Brian D, Jackson David J. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. Chest. 2021 Feb; 159(2): 496–506. DOI: 10.1016/j.chest.2020.08.2083.

Mark FitzGerald J, Bleecker Eugene R, Parameswaran Nair, Stephanie Korn, Ken Ohta, Marek Lommatzsch, Ferguson Gary T, Busse William W, Peter Barker, Stephanie Sproule, Geoffrey Gilmartin, Viktoria Werkström, Magnus Aurivillius, Mitchell Goldman, CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29; 388(10056): 2128–2141. DOI: 10.1016/S0140-6736(16)31322-8. 15. Benralizumab. [Online]. Retrieved on :27 Jun 2023.

Aasia Ghazi, Anita Trikha, Calhoun William J. Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012 Jan; 12(1): 113–8. DOI: 10.1517/14712598.2012.642359.

Diego Bagnasco, Matteo Ferrando, Gilda Varricchi, Francesca Puggioni, Giovanni Passalacqua, Giorgio Walter Canonica. Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma. Front Med. 2017 Aug 31; 4: 135. DOI: 10.3389/fmed.2017.00135. Retrieved on:28 Jun 2023.

Mayo clinic. Drugs supplements/benralizumab subcutaneous route/side effects. [Online]. Retrieved on:28 Jun 2023. Benralizumab. [Online]. Retrieved on:28 Jun 2023.

Fabio Luigi Massimo Ricciardolo, Francesca Bertolini, Vitina Carriero . The Role of Dupilumab in Severe Asthma. Biomedicines. 2021 Sep; 9(9): 1096. Doi: 10.3390/biomedicines9091096.

Daniella D’Ippolito, Michele Pisano. Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis. PT. 2018 Sep; 43(9): 532–535. articles/PMC6110636/. Retrieved on:29 Jun 2023. Retrieved on: 29 Jun2023.

Medical news today. Dupixent (Dupilumab). [Online]. articles/326617. Retrieved on:29 Jun 2023.[Online]. Retrieved on:30 Jun 2023.

Andrew Menzies-Gow, Jonathan Corren, Arnaud Bourdin, Geoffrey Chupp, Elliot Israel, Wechsler Michael E, Brightling Christopher E, Griffiths Janet M, Åsa Hellqvist, Karin Bowen, Primal Kaur, Gun Almqvist, Sandhia Ponnarambil, Gene Colice. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021 May 13; 384(19): 1800–1809. DOI: 10.1056/NEJMoa2034975. 27. Medline plus. Tezepelumab Injection. [Online]. html. Retrieved on:29 Jun 2023.

Menzies-Gow Andrew et al. NAVIGATOR: A phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respiratory Research. 2020; 21(1): 1–12. DOI:

U.S. Food and Drug Administration. 2021). FDA approves maintenance treatment for severe asthma. [Online] Available from: Retrieved on: 30 Jun 2023.

Jacox C. (2023). What is Tezepelumab? Side effects, benefits, and uses. Health Care Originals. [Online] Available at: Tezepelumab (Monograph). [Online]. tezepelumab.html. Retrieved on: 30 Jun 2023. Retrieved on:30 Jun 2023. 34. Healthcare originals. What is Tezepelumab side effects benefits and uses. [Online]. Retrieved on: 30 Jun 2023.



  • There are currently no refbacks.

Copyright (c) 2023 Trends in Drug Delivery